KRAS G12C Mutations in NSCLC: From Target to Resistance

Lung cancer represents the most common form of cancer, accounting for 1.8 million deaths globally in 2020. Over last decade treatment advanced and metastatic non-small cell lung have dramatically improved largely thanks to emergence two therapeutic breakthroughs: discovery immune checkpoint inhibitors targeting oncogenic driver alterations. While these therapies hold great promise, they face same limitation as other inhibitors: resistant mechanisms. One such alteration is Kirsten Rat Sarcoma (KRAS) oncogene. KRAS mutations are NSCLC, representing roughly 20–25% cases. The mutation almost exclusively detected adenocarcinoma found among smokers 90% time. Along with development new drugs that been showing promising activity, resistance mechanisms begun be clarified. aim this review unwrap biology NSCLC a specific focus on primary secondary their possible clinical implications.